Retatrutide vs Tirzepatide vs Semaglutide: A Research Comparison

By the Portal to Wellness Research Team · Reviewed for scientific accuracy prior to publication · Published June 2026 · ~7 min read

For research use only. This article summarizes peer-reviewed scientific literature about three incretin-receptor compounds for educational and comparative purposes. The compounds discussed are sold strictly for laboratory and analytical research. Nothing here is medical advice, a therapeutic claim, or a dosing instruction, and nothing here is intended to describe use in humans. Published clinical-trial figures cited below refer to the pharmaceutical drug products studied in those trials — not to research-grade compounds.

Three compounds dominate metabolic-research conversations right now: semaglutide, tirzepatide, and retatrutide. They are often grouped together as “GLP-1s,” but at the receptor level they are three genuinely different molecules — a single-receptor agonist, a dual agonist, and a triple agonist. If you are comparing them for research purposes, the differences in which receptors each one activates are the whole story. This guide breaks down the pharmacology, what the published literature reports, and the purity factors that matter when sourcing research material.

First, the incretin system in one minute

Incretins are gut hormones the body releases after eating. Two of the most studied are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). They influence insulin signaling, glucose handling, and satiety pathways. A third hormone, glucagon, works in the opposite direction on blood glucose but is also involved in energy expenditure and lipid metabolism. The three compounds below are distinguished by how many of these receptors they activate:

• Semaglutide → GLP-1 receptor only (mono-agonist)
• Tirzepatide → GIP + GLP-1 receptors (dual agonist)
• Retatrutide → GIP + GLP-1 + glucagon receptors (triple agonist)

For a deeper primer on the receptor itself, see our glossary entry on the GLP-1 receptor and amylin analogues.

Semaglutide — the single-receptor benchmark

Semaglutide is a GLP-1 receptor mono-agonist. It was the first of this modern wave to reach wide study, and it remains the reference point every newer molecule is measured against. In research models, GLP-1 receptor activation is associated with glucose-dependent insulin signaling and effects on satiety pathways. Because it engages a single receptor, semaglutide is the “cleanest” of the three to study mechanistically — there is only one pathway to attribute effects to.

Tirzepatide — adding the GIP receptor

Tirzepatide activates both the GIP and GLP-1 receptors. Interestingly, the published pharmacology shows it is not a balanced dual agonist: research characterizing the molecule describes it as an imbalanced and biased agonist that favors GIP-receptor activity, with roughly fivefold weaker affinity at the GLP-1 receptor than native GLP-1 itself.^[1] At the GLP-1 receptor it also shows signaling bias — favoring cAMP generation over β-arrestin recruitment.^[1]

Why researchers care about the added GIP arm: in the published literature, adding GIP-receptor agonism to GLP-1 agonism is associated with enhanced liberation of stored lipids from adipose tissue in study models.^[1] In a head-to-head pharmaceutical trial (SURPASS-2), tirzepatide produced superior glucose and weight reductions versus the highest approved dose of the GLP-1 mono-agonist semaglutide.^[2]

If your research focus is the dual-incretin mechanism, our Metabolic Research collection carries tirzepatide.

Retatrutide — the triple agonist

Retatrutide is the newest and most pharmacologically ambitious of the three: a triple agonist of the GIP, GLP-1, and glucagon receptors.^[3] That third receptor — glucagon — is what separates it from everything before it. Glucagon-receptor agonism is studied for its potential role in energy expenditure and hepatic lipid metabolism, which is why retatrutide has drawn so much attention in obesity and metabolic-dysfunction research.

The published phase 2 literature is what put it on the map. In a phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023), the pharmaceutical drug product was studied across multiple dose levels in adults with obesity; a separate phase 2 trial examined it in adults with type 2 diabetes.^[3][4] These are studies of the drug product in clinical populations — cited here to explain why the molecule is of research interest, not as a claim about research-grade material.

For the triple-agonist mechanism, see our research-use-only retatrutide and the retatrutide + cagrilintide combination.

Side-by-side comparison

What actually matters when sourcing research compounds

For research purposes, the molecule is only half the equation — what is actually in the vial is the other half. Three things to verify before trusting any research-compound source: a third-party Certificate of Analysis (COA) per batch reporting actual purity percentage, compound identity, and heavy-metal screening; identity confirmation matching the COA to the lot received; and transparent sourcing under documented manufacturing standards. This is why Portal to Wellness states its testing position plainly rather than implying coverage it does not have: no Certificate of Analysis is published at present, and the supplier-submitted certificates previously shown were withdrawn because they could not be independently verified. Read our full lab verification and quality testing position.

Frequently asked questions

What is the difference between a mono-, dual-, and triple-agonist?
It refers to how many incretin/metabolic receptors the compound activates. Semaglutide activates one (GLP-1), tirzepatide activates two (GIP and GLP-1), and retatrutide activates three (GIP, GLP-1, and glucagon).

Which has the most published research?
Semaglutide has the most mature literature as the established benchmark; tirzepatide has large head-to-head comparative data; retatrutide is the newest, with phase 2 trial literature published in 2023.

Are these compounds approved for human use?
The research-grade compounds sold here are for laboratory and research use only — not for human or veterinary use. Some of these molecules exist as approved pharmaceutical drug products studied in the clinical trials referenced above; those approvals and trials concern the drug products, not research-grade material.

About the author

The Portal to Wellness Research Team curates research-grade compounds and writes plain-language, citation-backed explainers for the research community. Learn more on our About page.

References

1. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526454/
2. Comparative pharmacology of tirzepatide vs. semaglutide (SURPASS-2). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060465/
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
4. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. https://pubmed.ncbi.nlm.nih.gov/37385280/

All products sold on this website are intended for research and identification purposes only. They are not intended for human dosing, injection, ingestion, or veterinary use. Must be 18 or older to purchase. This content is educational and is not medical advice.

📚 Part of our GLP-1 & Metabolic Research Guide research guide.